V. Harvey
- Cancer Research top 5%
- Breast Cancer Treatment Studies 7
- Oncology top 5%
- Cancer Treatment and Pharmacology 5
- HER2/EGFR in Cancer Research 4
- Cancer Risks and Factors 2
- Research and Theory top 10%
- Pathology and Forensic Medicine top 10%
-
- Hormonal and reproductive studies 3
-
- Prostate Cancer Treatment and Research 3
-
- Testicular diseases and treatments 2
-
- Neuroblastoma Research and Treatments 2
- Co-authors
- Roberto HeggAndreas SchneeweißG. RossChristoph TauschTamas HickishJavier CortésAlexandru EniuJayantha Ratnayake
- Journals
- British Journal of Cancer (4 papers)Journal of Clinical Oncology (4 papers)Annals of Oncology (2 papers)
- Partner nations
- New ZealandAustraliaUnited Kingdom
In The Last Decade
V. Harvey
20 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 91
- Cancer Research 520
- Oncology 833
- Research and Theory 25
- Radiology, Nuclear Medicine and Imaging 263
- Pathology and Forensic Medicine 122
Countries citing papers authored by V. Harvey
This map shows the geographic impact of V. Harvey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Harvey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Harvey more than expected).
Fields of papers citing papers by V. Harvey
This network shows the impact of papers produced by V. Harvey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Harvey. The network helps show where V. Harvey may publish in the future.
Co-authorship network
The 25 scholars most cited alongside V. Harvey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 2 | |
| 2 | Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)breakdown → | 2013 | 774 |
| 3 | 2012 | 17 | |
| 4 | 2011 | 44 | |
| 5 | 2010 | 8 | |
| 6 | 2009 | 51 | |
| 7 | 2007 | 2 | |
| 8 | 2007 | 52 | |
| 9 | 1997 | 42 | |
| 10 | 1992 | 22 | |
| 11 | 1991 | 17 | |
| 12 | 1990 | 20 | |
| 13 | 1990 | 15 | |
| 14 | 1990 | 2 | |
| 15 | 1988 | 48 | |
| 16 | 1988 | 4 | |
| 17 | 1988 | 3 | |
| 18 | 1987 | 0 | |
| 19 | 1986 | 1 | |
| 20 | The post endarterectomy carotid bruit. Evaluation by Duplex scan. | 1985 | 1 |
About V. Harvey
V. Harvey is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 1.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (7 papers), Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (4 papers), Hormonal and reproductive studies (3 papers), Prostate Cancer Treatment and Research (3 papers), Testicular diseases and treatments (2 papers), Neuroblastoma Research and Treatments (2 papers) and Cancer Risks and Factors (2 papers). The work is most often cited by research in Cancer Research (520 citations), Oncology (833 citations) and Research and Theory (25 citations). V. Harvey has collaborated with scholars based in New Zealand, Australia and United Kingdom. Frequent co-authors include Roberto Hegg, Andreas Schneeweiß, G. Ross, Christoph Tausch, Tamas Hickish, Javier Cortés, Alexandru Eniu, Jayantha Ratnayake, Stephen Chia and Jae Hong Seo. Their work appears in journals such as British Journal of Cancer, Journal of Clinical Oncology, Annals of Oncology, Cancer Research and Artificial Organs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.